ondansetron has been researched along with (2s,3s)-2-phenyl-3-((5-trifluoromethoxy-2-methoxy)benzylamino)piperidine in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Black, LS; D'Angelo, R; Dalby, PL; Gesztesi, Z; MacLean, D; Scuderi, PE; Wender, RH; White, PF; Wright, W | 1 |
1 trial(s) available for ondansetron and (2s,3s)-2-phenyl-3-((5-trifluoromethoxy-2-methoxy)benzylamino)piperidine
Article | Year |
---|---|
Substance P (Neurokinin-1) antagonist prevents postoperative vomiting after abdominal hysterectomy procedures.
Topics: Administration, Oral; Adult; Antiemetics; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hysterectomy; Injections, Intravenous; Neurokinin-1 Receptor Antagonists; Ondansetron; Piperidines; Placebos; Postoperative Nausea and Vomiting; Preanesthetic Medication; Risk Factors; Serotonin Antagonists; Substance P | 2000 |